RDNT

RadNet's DeepHealth gains FDA clearances for AI breast imaging tools that assess cardiovascular risk and compare prior mammograms.

SOMERVILLE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), announces it has received FDA 510(k) clearances for two new Breast Suite1 functionalities: Breast Arterial Calcification (BAC) Assessment, a tool applied to standard screening mammograms that automatically identifies breast arterial calcifications, a potential early indicator of cardiovascular disease;2 Prior exam integration into ProFound Pro, which enables automatic processing of prior and current studies to track prior lesions and distinguish new lesions, with the goal of improving cancer detection rates and reducing recalls.

LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of outpatient imaging centers and a premier developer of radiology digital health solutions, today announced that it has entered into Incremental Amendment No. 3 (the “Third Amendment”) to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the “Existing Credit Agreement” and, as amended by the Third Amendment, the “Credit Agreement”).

SOMERVILLE, Mass., June 10, 2026 (GLOBE NEWSWIRE) --  DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced the launch of Reporting Pro, a next-generation AI-powered solution designed to transform the way radiologists generate clinical reports and findings for their referring physicians.

LOS ANGELES, June 03, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of outpatient imaging centers and a premier developer of radiology digital health solutions, today announced that it seeks to secure an incremental term loan in the aggregate principal amount of $200 million (the “Proposed 2026 Incremental Term Loan”) pursuant to a proposed amendment (the “Proposed Amendment”) to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the “Existing Credit Agreement” and, the transaction, the “Loan Transaction”). If consummated, the Proposed 2026 Incremental Term Loan would be added to and form a part of the existing term loan under the Existing Credit Agreement (the “Existing Term Loan”).

Investors need to pay close attention to RDNT stock based on the movements in the options market lately.

RadNet hosts free webinar for Men's Health Month, featuring live Q&A and physicians presenting on coronary artery disease, prostate cancer and lung cancer.

Jefferies, an investment banking and capital management firm, has updated its ‘Franchise Picks' list, which features the company's highest-conviction ‘Buy' rated stocks.

RadNet, Inc. (RDNT) Q1 2026 Earnings Call Transcript

RadNet NASDAQ: RDNT reported record first-quarter 2026 revenue and adjusted EBITDA, with management saying demand for advanced imaging and the growing contribution of its Digital Health business helped offset severe winter weather disruptions on the East Coast.